Advancing regenerative
science for eye health
Exosomes are nanoscale vesicles secreted by cells that act as natural carriers of proteins, lipids, and genetic material. They play a vital role in intercellular communication and tissue repair. At YD Bio, we are developing exosome-based therapeutics derived from limbal stem cells to address large unmet needs in ophthalmology. Our goal is to use regenerative science to improve ocular surface health, enhance patient comfort, and deliver longer-lasting solutions for chronic eye conditions.
Why Limbal Stem Cell–Derived Exosomes?
Regenerative potential:
Support repair and renewal of stressed or damaged ocular surface tissues.
Beyond symptom relief:
Unlike conventional dry eye therapies that focus on temporary comfort, exosomes act at the cellular level to address underlying dysfunction.
Broader applications:
While initial development focuses on dry eye disease, the platform has potential to expand into other ocular surface disorders.
Potential Advantages of Our LSC Exosomes
Demonstrated Potential for Safety and Compatibility
Limbal stem cells (LSCs) have shown the potential to reduce immune rejection risks, supporting the development of safer and more compatible therapeutic approaches.
Superior Production Technology
Our patented process enables a 20-fold increase in cell growth within five days in preclinical evaluations. This efficiency has the potential to shorten production timelines and expand treatment accessibility.
Exclusive Distribution Rights
YD Bio holds the exclusive global marketing and distribution rights for 3D Global Biotech’s investigational technologies, ensuring access to innovative therapeutic platforms with worldwide reach.
Scalable and Reliable Supply
3D Global Biotech’s advanced manufacturing capabilities are designed to provide consistent, high-quality production at scale, helping YD Bio meet future global demand.